Category: Research
-
Delic Holdings (DELC.C) acquires licensed psilocybin/cannabis lab, is doing legal shroom business
For a year, naysayers have dismissed the early stage shroom boom as being a pumpy bunch of pubco RTOs that won’t be able to do business legally for years. To be fair, there’s some basis to that dismissal. But only some. We’ve also been talking about how Delic Holdings (DELC.C) was an all-star team of…
-
Pure Extracts (PULL.C) cuts a licensing deal with Taste-T, the maker of Fireball Cannabis Gummies
Included in the agreement is the delivery to Pure Extracts’ British Columbia facility of one of Taste-T’s custom built gummie-manufacturing machines, certified to Canadian standards.
-
Canntab (PILL.C) yeets another patent for hard-pressed, long release cannabis pills
I’ve made no secret of the fact that the Canadian cannabis market frequently annoys the hell out of me. What I want is for it to be a mature space that more and more adults are making use of, and that is free to innovate, free to be excellent, free to market itself properly, and…
-
![Xphyto’s (XPHY.C) lays out its ambitious Parkinson’s/Epilepsy/Depression/Multiple Sclerosis drug formulation strategy which includes heavy investment in psychedelic medicine]()
Xphyto’s (XPHY.C) lays out its ambitious Parkinson’s/Epilepsy/Depression/Multiple Sclerosis drug formulation strategy which includes heavy investment in psychedelic medicine
Xphyto describes itself as “a bioscience accelerator” “targeting growth through commercialization of its product pipeline”.
-
Core One Labs (COOL.C): Out of the ashes, a new business model and supportive shareholder base
In my experience with the North American public markets, few companies and executive teams got more lucky with their shareholder base than Lifestyle Delivery Systems. Their initial pitch was simple – they’d put extracted cannabis on thin film strips for easy and precise ingestion – and I, along with a ton of others, shoveled money…
-
Cannabis extractor Pure Extracts (PULL.C) stakes claim in the rocketing mushroom space
Barely a few weeks after telling the Equity.Guru audience that the timeline on mushrooms would see Pure Extracts (PULL.C) focusing on its core cannabis market, evolving market dynamics and a renewed focus on the potential of psychedelics have seen the company hit the gas on its long term shroom plans. With interest in functional and…
-
Delic Holdings (DELC.C) emerges as a psychedelics play aimed at executing real, legal business, and right now
Smallcap investors largely see the psychedelics space in one of two ways; you’re either in the ‘this may be big one day but there’s not a lot of fat on the bones just yet so I’ll wait’ camp, or the ‘fat schmat, everything is a trade and who cares about tomorrow’ camp. I’m pegged pretty…
-
![Revive (RVV.C) advances mushroom bio-tech as new regs change the game]()
Revive (RVV.C) advances mushroom bio-tech as new regs change the game
On November 11, 2020 Revive Therapeutics (RVV.C) Revive Therapeutics updated shareholders on its oral thin-film delivery system with psilocybin being developed “under a research partnership agreement with Reed Research Group out of the University of Wisconsin-Madison”. RVV is a specialty life sciences company focused on the R&D of therapeutics for medical needs and rare disorders.…
-
![Xphyto (XPHY.C) advances its Oral Dissolvable Film (ODF) technology for CBD and THC medical markets]()
Xphyto (XPHY.C) advances its Oral Dissolvable Film (ODF) technology for CBD and THC medical markets
Increased product efficacy and patient convenience is anticipated through faster onset of drug action, more predictable therapeutic activity and ease of use.
-
Revive Therapeutics (RVV.C) blasts off, up 68% after FDA Phase 3 COVID-19 approval
Formerly dismissed-by-many pharmaceutical company Revive Therapeutics (RVV.C) jumped a whopping 68% Friday upon revealing it has been granted approval to move forward with phase 3 clinical trials on the use of its Bucillamine medication as a potential treatment for patients with mild to moderate COVID-19. The U.S. Food and Drug Administration (FDA) has approved Revive…
